Overview of Comments Received on 'Draft Questions and Answers on Data Monitoring Committees Issues' (EMA/492010/2018)

On 29 January 2021 the EMA published the overview of comments on draft Q&A on Data Monitoring Committees Issues.

The aim of this question-and-answer document is to supplement the CHMP Data Monitoring Committee guideline (Doc. Ref. EMEA/CHMP/EWP/5872/03) by providing clarification on the role and necessity for a Data Monitoring Committee (DMC) in different phases of drug development and throughout the product lifecycle as well as with regard to the responsibilities for implementing DMC decisions.

Read the pdf 
Copyright Widler & Schiemann AG 2020. All Rights Reserved. /